ARGNF
Price
$833.50
Change
+$33.50 (+4.19%)
Updated
Oct 6 closing price
Capitalization
50.99B
MNKD
Price
$5.47
Change
+$0.12 (+2.24%)
Updated
Oct 17 closing price
Capitalization
1.68B
23 days until earnings call
Interact to see
Advertisement

ARGNF vs MNKD

Header iconARGNF vs MNKD Comparison
Open Charts ARGNF vs MNKDBanner chart's image
Argen X
Price$833.50
Change+$33.50 (+4.19%)
Volume$3
Capitalization50.99B
MannKind
Price$5.47
Change+$0.12 (+2.24%)
Volume$5.62M
Capitalization1.68B
ARGNF vs MNKD Comparison Chart in %
ARGNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARGNF vs. MNKD commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGNF is a Hold and MNKD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (ARGNF: $833.50 vs. MNKD: $5.47)
Brand notoriety: ARGNF and MNKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARGNF: 87% vs. MNKD: 114%
Market capitalization -- ARGNF: $50.99B vs. MNKD: $1.68B
ARGNF [@Biotechnology] is valued at $50.99B. MNKD’s [@Biotechnology] market capitalization is $1.68B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARGNF’s FA Score shows that 1 FA rating(s) are green whileMNKD’s FA Score has 0 green FA rating(s).

  • ARGNF’s FA Score: 1 green, 4 red.
  • MNKD’s FA Score: 0 green, 5 red.
According to our system of comparison, ARGNF is a better buy in the long-term than MNKD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARGNF’s TA Score shows that 1 TA indicator(s) are bullish while MNKD’s TA Score has 5 bullish TA indicator(s).

  • ARGNF’s TA Score: 1 bullish, 2 bearish.
  • MNKD’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MNKD is a better buy in the short-term than ARGNF.

Price Growth

ARGNF (@Biotechnology) experienced а 0.00% price change this week, while MNKD (@Biotechnology) price change was +12.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

MNKD is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARGNF($51B) has a higher market cap than MNKD($1.68B). MNKD has higher P/E ratio than ARGNF: MNKD (49.73) vs ARGNF (42.42). ARGNF YTD gains are higher at: 27.769 vs. MNKD (-14.930). ARGNF has higher annual earnings (EBITDA): 690M vs. MNKD (79.1M). ARGNF has more cash in the bank: 3.93B vs. MNKD (179M). ARGNF has less debt than MNKD: ARGNF (43.2M) vs MNKD (46.8M). ARGNF has higher revenues than MNKD: ARGNF (3.05B) vs MNKD (302M).
ARGNFMNKDARGNF / MNKD
Capitalization51B1.68B3,039%
EBITDA690M79.1M872%
Gain YTD27.769-14.930-186%
P/E Ratio42.4249.7385%
Revenue3.05B302M1,011%
Total Cash3.93B179M2,194%
Total Debt43.2M46.8M92%
FUNDAMENTALS RATINGS
ARGNF vs MNKD: Fundamental Ratings
ARGNF
MNKD
OUTLOOK RATING
1..100
5024
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
648
SMR RATING
1..100
39100
PRICE GROWTH RATING
1..100
4145
P/E GROWTH RATING
1..100
7798
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNKD's Valuation (79) in the Biotechnology industry is in the same range as ARGNF (81) in the null industry. This means that MNKD’s stock grew similarly to ARGNF’s over the last 12 months.

ARGNF's Profit vs Risk Rating (6) in the null industry is somewhat better than the same rating for MNKD (48) in the Biotechnology industry. This means that ARGNF’s stock grew somewhat faster than MNKD’s over the last 12 months.

ARGNF's SMR Rating (39) in the null industry is somewhat better than the same rating for MNKD (100) in the Biotechnology industry. This means that ARGNF’s stock grew somewhat faster than MNKD’s over the last 12 months.

ARGNF's Price Growth Rating (41) in the null industry is in the same range as MNKD (45) in the Biotechnology industry. This means that ARGNF’s stock grew similarly to MNKD’s over the last 12 months.

ARGNF's P/E Growth Rating (77) in the null industry is in the same range as MNKD (98) in the Biotechnology industry. This means that ARGNF’s stock grew similarly to MNKD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARGNFMNKD
RSI
ODDS (%)
N/A
Bearish Trend 7 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
29%
Bullish Trend 3 days ago
88%
Momentum
ODDS (%)
N/A
Bearish Trend 3 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
21%
Bearish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
33%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
31%
Bullish Trend 3 days ago
76%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
N/A
Bearish Trend 10 days ago
80%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
86%
Aroon
ODDS (%)
Bullish Trend 3 days ago
12%
Bullish Trend 7 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ARGNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RPXIX31.320.16
+0.51%
RiverPark Large Growth Institutional
IEDAX11.850.06
+0.51%
Voya Large Cap Value A
GQETX36.640.15
+0.41%
GMO Quality III
FSCCX33.020.12
+0.36%
Nuveen Small Cap Value I
MTCLX83.060.16
+0.19%
MFS Technology R6

ARGNF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARGNF has been loosely correlated with ARGX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGNF jumps, then ARGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARGNF
1D Price
Change %
ARGNF100%
N/A
ARGX - ARGNF
54%
Loosely correlated
+0.76%
MNKD - ARGNF
30%
Poorly correlated
+2.24%
TNXP - ARGNF
25%
Poorly correlated
-1.01%
ROIV - ARGNF
24%
Poorly correlated
+0.88%
IMVT - ARGNF
24%
Poorly correlated
+0.57%
More

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with IONS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then IONS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
+2.24%
IONS - MNKD
48%
Loosely correlated
+0.03%
VCYT - MNKD
44%
Loosely correlated
+0.06%
LXRX - MNKD
42%
Loosely correlated
-3.40%
CYTK - MNKD
42%
Loosely correlated
-0.88%
INSM - MNKD
40%
Loosely correlated
+1.57%
More